William Larchian, M.D.
| Appointed: |
1997 |
| Gender: |
Male |
| Languages: |
English |
Urology
Urology
Biographical Sketch
William A. Larchian, MD, joined Cleveland Clinic in 1997 as a member of the Urological Institute. He received his undergraduate, graduate and medical degrees from Boston University. Following his urologic residency, he completed a combined fellowship at Duke University and Memorial Sloan-Kettering Cancer Center in urologic oncology as an American Foundation for Urologic Disease award recipient.
Dr. Larchian's primary interests are in the treatment of urologic malignancies including kidney, prostate, bladder and testicular cancers. He has a special focus on immunologic treatment for superficial bladder cancer. He also performs traditional surgical as well as minimally invasive techniques such as brachytherapy and cryoablation for the treatment of prostate cancer.
Dr. Larchian has a research laboratory in Cleveland Clinic's Lerner Research Institute, with the primary focus of gene therapy for bladder cancer. Additional projects are evaluating new, innovative methods utilizing immunotherapy for the treatment of bladder cancer.
Professional Highlights
- American Foundation for Urologic Disease Scholarship and Award, 1993-1995
Education & Fellowships
| Medical School: | Boston University School of Medicine, Boston, MA |
|
| Residency: | Boston Medical Center, Urology, Boston, MA |
| Residency: | University of Massachusetts Medical Center, General Surgery, Worcester, MA |
| Fellowship: | Memorial Sloan-Kettering Cancer Center, Urology, New York, NY |
| Fellowship: | Memorial Sloan-Kettering Cancer Center, Surgical Oncology, New York, NY |
| Other Education: | (Undergraduate) Boston University, Boston, MA |
Specialty Interests
Gene therapy for urologic tumors, Prostate Disease, urologic oncology.
Innovations & Patents
In 1999, Dr. Larchian was the first member of the Cleveland Clinic to utilize intravesical interferon as part of the immunotherapeutic treatment of superficial bladder cancer. This treatment is now a well-accepted option for bladder cancer therapy.
Dr. Larchian was also among the first to offer brachytherapy and cryoablation for the treatment of prostate cancer.
Awards & Honors
Research Funding, Flight Attendants Medical Research Institute (FAMRI) award and grant to evaluate the effects of secondhand smoke during bladder cancer treatment, 2008-2011
Professional Memberships
- Ohio State Medical Association
- American Association of Clinical Urologists
- American College of Surgeons
- American Urological Association
- Massachusetts Medical Society
Specializes in Diseases and Conditions
Specializes in Services
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland Clinic’s procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its doctors’ connections with industry and those of their immediate family members. As of 9/6/2008, Dr. Larchian has reported the financial relationships with the companies listed below. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic’s policies on collaborations with industry and innovation management, go to our
Integrity in Innovation page.
Consulting. Dr. Larchian receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
( † Disclaimer: This search is powered by PubMed, a service of the U.S.
National Library of Medicine. PubMed is a third-party website with no
affiliation with Cleveland Clinic.)
